Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 2/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.31 |
| ▸ | FEN1 | P39748 | 4/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825921 | 0.90 | BACE1 (0.37) | APPBACE1GLO1KIF11TRPV1 | |
| SCHEMBL10276333 | 0.87 | ADORA1 (0.33) | TDP2HSD11B1ALOX5APFEN1 | |
| SCHEMBL10275411 | 0.86 | APP (0.37) | APPAKR1C3AKR1C2ADAM17TDP2 | |
| SCHEMBL10275481 | 0.83 | ADAM17 (0.35) | APPAKR1C3AKR1C2ADAM17TDP2 | |
| SCHEMBL10275773 | 0.82 | APP (0.34) | APPAKR1C3AKR1C2ADAM17TDP2 | |
| SCHEMBL10276695 | 0.81 | KIF11 (0.33) | KIF11HSD11B1ALOX5APFEN1 | |
| SCHEMBL10276350 | 0.76 | PDE3B (0.34) | TDP2KIF11 | |
| SCHEMBL10275694 | 0.75 | TDP2 (0.35) | ADAM17TDP2 | |
| SCHEMBL10275632 | 0.73 | RAD51 (0.33) | BACE1TDP2KIF11 | |
| SCHEMBL10275638 | 0.73 | KCNH2 (0.36) | ADAM17TDP2ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | APP 55/4885BACE1 47/4885AKR1C3 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.